Posts Feed
Comments Feed

Archive for the 'Lung Cancer' Category

CB1400, Patented By Canopus BioPharma, Prevents Tumor Growth And Enhances The Anti-Tumor Effects Of Cisplatin And Cetuximab (Erbitux)

Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice lung cancer models. Chairman of Canopus BioPharma, Dr.

More: continued here

No Comments »

New Clinical Trial For Patients With Asbestos-Associated Lung Cancer

The Mesothelioma Center within the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital and Columbia University Medical Center is now recruiting patients for a clinical research study of a new targeted radiation and chemotherapy protocol for pleural mesothelioma, a cancer of the lung’s lining that is almost always caused by previous exposure to asbestos.

More: continued here

No Comments »

Researchers Optimistic About New Therapy For Lung Cancer

An article in the July edition of The Lancet Oncology suggests that a common treatment for liver cancer - radiofrequency ablation - can also be used to treat lung cancer. A team of European and American researchers calls for randomized controlled trials in order to more robustly investigate this minimally invasive procedure for cancer treatment. In both men and women, lung cancer causes the most cancer deaths, and 80% of these are non-small-cell lung cancer (NSCLC).

More: continued here

No Comments »

Hi-Tech Radiation Zaps “Moving Targets” On Lungs - Powerful Radiation Therapy Yields Remarkable Results In Lung Cancers

It might surprise you to know that lung cancer claims more lives than breast, colon, and prostate cancers combined. Part of the problem is that lung cancer is often diagnosed late, so there aren’t as many treatment options for patients. Now, that may be changing. Doctors are now using powerful radiation beams to zap lung tumors and give patients new hope. Arthur Koscielnaik knows how lucky he is to be able to share special moments with his children.

More: continued here

No Comments »

Five-Year Project Will Examine Health Effects Of Exposure To Libby Amphibole Asbestos

The U.S. Department of Health and Human Services (HHS) and the U.S. Environmental Protection Agency (EPA) announced the Libby Amphibole Health Risk Initiative, a series of projects totaling $8 million designed to understand the health effects of exposure to lower levels of Libby, Montana asbestos (i.e., Libby amphibole).

More: continued here

No Comments »

For Smokers, Lung Cancer Risk Not Greater For Women

A paper published in The Lancet Oncology hasconcluded that women smokers are not at a greater risk of developinglung cancer than male smokers. However, among those who have neversmoked, women appear to be more likely to develop the disease than men.In the United States, the medical and health community mostly agreesthat cigarette smoking is responsible for about 90% of lung cancers.

More: continued here

No Comments »

CT Lung Cancer Screening No Cure-All For Smokers

Screening for lung cancer with computed tomography (CT) may help reduce lung cancer deaths in current and former smokers, but it won’t protect them from other causes of death associated with smoking, according to a new study published in the July issue of the journal Radiology.”Our study suggests that screening may be one way to reduce risk of death from lung cancer,” said the study’s lead author, Pamela McMahon, Ph.D.

More: continued here

No Comments »

Enrolment Started For LUX-Lung 1 Study Oncology Research Programme

Boehringer Ingelheim is making progress in its oncology research programme, particularly in the most common form of lung cancer, non-small cell lung cancer (NSCLC). The first pivotal study for BIBW 2992 has now begun patient enrolment. The LUX-Lung 1 study is a randomized, double-blind phase IIb/III study. It will aim to determine the efficacy of BIBW 2992 plus best supportive care (BSC) compared to placebo plus BSC.

More: continued here

No Comments »

One Step Closer To Tailored Treatment For Lung Cancer

A major study released in the Journal of Clinical Oncology has shown that doctors could increase the survival of patients with a specific type of lung cancer to over 12 months, if they match choice of chemotherapy with the type of tissue in a patient’s tumour. Mick Peake, Lung Cancer Specialist and Chair of the Clinical Reference Group for the UK Lung Cancer Coalition (UKLCC) commented, “This is a very important opportunity to re-assess how we treat people with NSCLC.

More: continued here

No Comments »

Finger Clubbing: Leeds Medics Solve An Ancient Riddle And Offer New Tool For Diagnosis

A puzzling medical condition, identified more than 2,000 years ago by Hippocrates, has finally been explained by researchers at the University of Leeds.The phenomenon of “finger clubbing”, a deformity of the fingers and fingernails, has been known for thousands of years, and has long been recognized to be a sign of a wide range of serious diseases - especially lung cancer.

More: continued here

No Comments »

Next »